Live vs. Killed Vaccines

Note: In addition to immuncompromised patients (in most cases), pregnant women should not receive live vaccines because of a theoretic risk of transmitting the live agent to the fetus

Immune Deficiency Foundation Medical Advisory Committee (2014)

CDC Vaccination of Immunocompromised (Primary and Secondary) Persons

CDC Contraindications for MMR/Varicella for Patients on Biologics

Abatacept	Orencia	CTLA-4
Adalimumab	Humira	TNF blocker
Alefacept	Amevive	CD2
Alemtuzumab	Campath	Anti-CD52
Anakinra	Kineret	IL-1
Basiliximab	Simulect	IL-2R/CD25
Bevacizumab	Avastin	VEGF
Certolizumab pegol	Cimzia	TNF blocker
Cetuximab	Erbitux	EGFR
Daclizumab	Zenapax	IL-2R
Etanercept	Enbrel	TNF blocker
Glatiramer acetate	Copaxone	Immunomodulatory; target unknown
Golimumab	Simponi	TNF blocker
Ibritumomab tiuxetan	Zevalin	CD20 with radioisotope
Imatinib mesylate	Gleevec, STI 571	Signal transduction inhibitor/ protein-tyrosine kinase inhibitor
Infliximab	Remicade	TNF blocker
Interferon alfa	Pegasys, PegIntron	Block hepatitis C viral replication
Interferon beta-1a	Avonex, Rebif	Immunomodulatory; target unknown
Interferon beta-1b	Betaseron	Immunomodulatory; target unknown
Natalizumab	Tsabri	α4-integrin
Panitumumab	Vectibix	EGFR
Rilonacept	Arcalyst	IL-1
Rituximab	Rituxan	CD20
Sunitinib malate	Sutent	Multikinase inhibitor
Tocilizumab	Actemra	IL-6
Tositumomab	Bexxar	CD20 with radioisotope
Trastuzumab	Herceptin	Human EGFR 2 (HER2)
Ustekinumab	Stelara	IL-12, IL-23

References

Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts - JACI 2014.pdf

• Details
• Download
• 157 KB